Sutro Biopharma, Inc.
STRO · Nasdaq · United States
Share price · STRO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when STRO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Oct 2026-17.1%
Nothing announced by STRO that day or the session before.
- 9 Oct 2026-6.9%
Nothing announced by STRO that day or the session before.
- 12 Aug 2026-14.9%
- 22 May 2026-16.5%
Nothing announced by STRO that day or the session before.
- 18 May 2026-11.5%
Nothing announced by STRO that day or the session before.
- 20 Apr 2026+9.6%
Nothing announced by STRO that day or the session before.
- 24 Mar 2026+10.5%
- 6 Mar 2026+12.4%
Nothing announced by STRO that day or the session before.
- 19 Feb 2026+12.2%
Nothing announced by STRO that day or the session before.
- 10 Feb 2026+11.9%
Share of unusual movement by asset
For each asset, the share of STRO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
STRO-004events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 2% |
| Other company news (earnings, financing, releases naming no asset) | — | 16% |
| Sessions with no dated event | — | 82% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Tissue Factor (TF)Antibody–drug conjugate | Non-Small Cell Lung Cancer |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $9.1M | $24M | $47M+ $95M short-term inv. | $31M-$22M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $9.8M | $32M | $54M+ $110M short-term inv. | $39M-$38M operating cash flow | report ↗ |
| 2026-Q1 | $15M | $37M | $74M+ $129M short-term inv. | $38M-$42M operating cash flow | report ↗ |
| 2025-Q3 | $9.7M | $40M | $66M+ $102M short-term inv. | $57M-$38M operating cash flow | report ↗ |
| 2025-Q2 | $64M | $38M | $64M+ $141M short-term inv. | $12M-$45M operating cash flow | report ↗ |
| 2025-Q1 | $17M | $52M | $106M+ $143M short-term inv. | $76M-$68M operating cash flow | report ↗ |
| 2024-Q3 | $8.5M | $62M | $175M+ $214M short-term inv. | $49M-$65M operating cash flow | report ↗ |
| 2024-Q2 | $26M | $62M | $91M+ $285M short-term inv. | $48M$9.5M operating cash flow | report ↗ |
| 2024-Q1 | $13M | $57M | $65M+ $202M short-term inv. | $58M-$65M operating cash flow | report ↗ |
| 2023-Q3 | $17M | $46M | $82M+ $239M short-term inv. | $49M-$34M operating cash flow | report ↗ |
| 2023-Q2 | $10M | $42M | $235M+ $123M short-term inv. | $39M-$31M operating cash flow | report ↗ |
| 2023-Q1 | $13M | $39M | $62M+ $189M short-term inv. | $50M-$61M operating cash flow | report ↗ |
| 2022-Q3 | $25M | $32M | $97M+ $191M short-term inv. | $19M$66M operating cash flow | report ↗ |
| 2022-Q2 | $28M | $32M | $79M+ $113M short-term inv. | $26M-$3.2M operating cash flow | report ↗ |
| 2022-Q1 | $5.9M | $30M | $29M+ $143M short-term inv. | $39M-$35M operating cash flow | report ↗ |
| 2021-Q3 | $8.5M | $27M | $31M+ $159M short-term inv. | $31M-$24M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $102M | $166M | $58M+ $83M short-term inv. | $48M-$177M operating cash flow | report ↗ |
For FY2025, Sutro Biopharma reported revenue of $102.48M, up 65.2% YoY from $62.04M, with R&D spend of $166.42M, down 34.0% YoY. Cash and equivalents were $58.13M, while total cash, cash equivalents and marketable securities were $141.4M as of December 31, 2025. Net loss was $191.09M.
Management guided that the recent $110.0M gross offering extends the cash runway into at least the second quarter of 2028. In the clinic, the Phase 1 trial of STRO-004 has completed dosing across three cohorts with initial data expected in mid-2026, STRO-006 is expected to enter clinical development in 2026, and STRO-227’s IND submission is targeted for 2026. Under the Astellas collaboration, the first dual-payload iADC program has entered the clinic and a second program entered IND-enabling toxicology, triggering milestone payments of $10M and $7.5M respectively.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $62M | $252M | $190M+ $127M short-term inv. | $57M-$192M operating cash flow | report ↗ |
| 2023-FY | $154M | $180M | $69M+ $264M short-term inv. | $27M-$112M operating cash flow | report ↗ |
| 2022-FY | $68M | $137M | $47M+ $255M short-term inv. | $30M$3.5M operating cash flow | report ↗ |
| 2021-FY | $62M | $104M | $30M+ $130M short-term inv. | $26M-$82M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-18 | Gerber Hans-Peter · CHIEF SCIENTIFIC OFFICER | Option exercise | 3,750 | — | — | Form 4 |
| 2026-09-18 | Gerber Hans-Peter · CHIEF SCIENTIFIC OFFICER | Tax withholding | 1,345 | $15.34 | $21K | Form 4 |
| 2026-09-18 | Gerber Hans-Peter · CHIEF SCIENTIFIC OFFICER | Option exercise (derivative) | 3,750 | — | — | Form 4 |
| 2026-06-05 | MATSUI CONNIE · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-06-05 | Dybbs Michael · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-06-05 | Hunter Heidi · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-06-05 | Jagpal Sukhi · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-06-05 | Lobacki Joseph M · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 71 reporting institutions held 14.1M shares ($342.7M, 85.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BVF INC/IL | 1,251,788 | $31.2M |
| 2 | Affinity Asset Advisors, LLC | 1,069,519 | $26.6M |
| 3 | SAMSARA BIOCAPITAL, LLC | 1,062,872 | $26.5M |
| 4 | Kynam Capital Management, LP | 872,558 | $21.7M |
| 5 | ORBIMED ADVISORS LLC | 801,144 | $20.0M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 720,442 | $17.9M |
| 7 | PERCEPTIVE ADVISORS LLC | 715,307 | $17.8M |
| 8 | RA CAPITAL MANAGEMENT, L.P. | 715,307 | $17.8M |
| 9 | EVENTIDE ASSET MANAGEMENT, LLC | 715,307 | $17.8M |
| 10 | Point72 Asset Management, L.P. | 692,111 | $17.2M |
| 11 | ADAR1 Capital Management, LLC | 524,441 | $13.1M |
| 12 | Velan Capital Investment Management LP | 512,160 | $12.8M |
| 13 | Balyasny Asset Management L.P. | 465,792 | $11.6M |
| 14 | Woodline Partners LP | 457,441 | $11.4M |
| 15 | UBS Group AG | 392,871 | $9.8M |